A recent prospective imaging study determined that the overall prevalence of older adults with cerebral cavernous malformation (CCM) is 0.46%. The findings and data from this study are important for determining the potential number of patients available for cohort studies and anticipated clinical trials in patients with CCM. Researchers included 4,721 participants aged 50 to 89 years who were enrolled between January 1, 2004, and December 15, 2015, in the Mayo Clinic Study of Aging, a longitudinal, population-based study. Participants were invited to undergo brain magnetic resonance imaging (MRI). Of total participants, 2,715 had an evaluable MRI. They found:
- Of total participants who underwent MRI scans, 12 (0.44%) had CCM.
- With the use of inverse probability weights to adjust for participation bias, the overall prevalence was 0.46%.
- The age-adjusted prevalence was found to be 0.61% for the 50- to 59-year age group, 0.17% for the 60- to 69-year age group, 0.45% for the 70- to 79-year age group, and 0.58% for the 80- to 89-year age group.
- The sex-adjusted prevalence was 0.41% for women and 0.51% for men.
Flemming KD, Graff-Radford J, Aakre J, et al. Population-based prevalence of cerebral cavernous malformations in older adults. Mayo Clinic Study of Aging. [Published online ahead of print May 8, 2017]. JAMA Neurol. doi:10.1001/jamaneurol.2017.0439.
This Week's Must Reads
Midlife Risk Factors Linked to Late-Onset Epilepsy, JAMA Neurology; ePub 2018 Jul 23; Johnson, et al
Nearly 1 Million Adults ≥55 Years Have Epilepsy, Epilepsy Behav; ePub 2018 Aug 2; Sapkota, et al
Incidental Findings Common in Stroke Patients, J Stroke Cerebrovasc Dis; ePub 2018 Aug 2; Doyle, et al
Spatial Heterogeneity of White Matter Lesions , Neurology; ePub 2018 Aug 3; Habes, et al
Poor Sleep Linked to Slow Recovery from TBI, Sleep; ePub 2018 Jul 24; Kalmbach, Conroy, et al
Must Reads in Rare Diseases
FDA Approves Hizentra for CIDP Treatment, CSL Behring news release; 2018 Mar 16
Cerebral Cavernous Malformation in the Elderly , JAMA Neurol; ePub 2017 May 8; Flemming, et al
Austedo Approved to Treat Chorea in Huntington's Disease, Teva news release; 2017 Apr 3
Behavioral Impairment Linked to Depression in ALS, Neurology; ePub 2016 Aug 5; Rabkin, Goetz, et al
Environmental Toxins Associated with ALS, JAMA Neurol; ePub 2016 May 9; Su, et al